Zhongzhi Pharmaceutical Holdings Limited (3737.HK)
HKD 0.89
(-2.2%)
HKD 0.89
(-2.2%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.04 Billion CNY | 12.26% |
| 2022 | 1.82 Billion CNY | 4.55% |
| 2021 | 1.74 Billion CNY | 8.89% |
| 2020 | 1.6 Billion CNY | 19.5% |
| 2019 | 1.34 Billion CNY | 17.51% |
| 2018 | 1.14 Billion CNY | 20.91% |
| 2017 | 944.63 Million CNY | 29.32% |
| 2016 | 730.47 Million CNY | 6.17% |
| 2015 | 688.03 Million CNY | 15.53% |
| 2014 | 595.56 Million CNY | 23.36% |
| 2013 | 482.8 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 1.08 Billion CNY | 13.91% |
| 2023 Q2 | 1.09 Billion CNY | 11.72% |
| 2023 FY | 2.04 Billion CNY | 12.26% |
| 2023 Q4 | 955.48 Million CNY | -12.69% |
| 2022 FY | 1.82 Billion CNY | 4.55% |
| 2022 Q2 | 846.39 Million CNY | -1.56% |
| 2022 Q4 | 979.53 Million CNY | 15.73% |
| 2021 FY | 1.74 Billion CNY | 8.89% |
| 2021 Q2 | 886.71 Million CNY | 2.37% |
| 2021 Q4 | 859.78 Million CNY | -3.04% |
| 2020 Q2 | 737.67 Million CNY | 4.45% |
| 2020 FY | 1.6 Billion CNY | 19.5% |
| 2020 Q4 | 866.2 Million CNY | 17.42% |
| 2019 FY | 1.34 Billion CNY | 17.51% |
| 2019 Q4 | 706.26 Million CNY | 11.06% |
| 2019 Q2 | 635.91 Million CNY | 8.61% |
| 2018 Q2 | 556.66 Million CNY | 8.49% |
| 2018 FY | 1.14 Billion CNY | 20.91% |
| 2018 Q4 | 585.48 Million CNY | 5.18% |
| 2017 Q2 | 431.53 Million CNY | 16.16% |
| 2017 Q4 | 513.1 Million CNY | 18.9% |
| 2017 FY | 944.63 Million CNY | 29.32% |
| 2016 Q4 | 371.5 Million CNY | 3.49% |
| 2016 FY | 730.47 Million CNY | 6.17% |
| 2016 Q2 | 358.96 Million CNY | 5.35% |
| 2015 Q4 | 340.73 Million CNY | -1.89% |
| 2015 Q2 | 347.3 Million CNY | 12.94% |
| 2015 FY | 688.03 Million CNY | 15.53% |
| 2014 FY | 595.56 Million CNY | 23.36% |
| 2014 Q2 | 288.06 Million CNY | 93.47% |
| 2014 Q4 | 307.5 Million CNY | 6.75% |
| 2013 FY | 482.8 Million CNY | 0.0% |
| 2013 Q4 | 148.89 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 259.15 Million HKD | -690.951% |
| Grand Pharmaceutical Group Limited | 10.52 Billion HKD | 80.533% |
| Extrawell Pharmaceutical Holdings Limited | 59.09 Million HKD | -3368.496% |
| Wai Yuen Tong Medicine Holdings Limited | 783.88 Million HKD | -161.495% |
| Qianhai Health Holdings Limited | 961.29 Million HKD | -113.235% |
| Lee's Pharmaceutical Holdings Limited | 1.05 Billion HKD | -94.658% |
| Essex Bio-Technology Limited | 1.7 Billion HKD | -20.114% |
| Tongfang Kontafarma Holdings Limited | 809.1 Million HKD | -153.343% |
| PuraPharm Corporation Limited | 406.85 Million HKD | -403.814% |
| SSY Group Limited | 6.46 Billion HKD | 68.284% |
| JBM (Healthcare) Limited | 648.41 Million HKD | -216.127% |
| Jacobson Pharma Corporation Limited | 1.46 Billion HKD | -39.652% |
| China Resources Pharmaceutical Group Limited | 270.39 Billion HKD | 99.242% |